Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

If approved, SER-109 expected to be the first-ever FDA-approved oral microbiome therapeutic PDUFA target action date is April 26, 2023, with anticipated launch soon thereafter FDA advised that they are not currently planning to hold an Advisory...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news